Skip to main content

Single Intravenous Dose Kinetics and Accumulation of Atenolol in Patients with Impaired Renal Function and on Hemodialysis

  • Conference paper
Further Studies in the Assessment of Toxic Actions

Part of the book series: Archives of Toxicology ((TOXICOLOGY,volume 4))

Abstract

The concentration of atenolol in plasma and urine was determined following an intravenous (i.v.) dose given to 17 hypertensive patients with a glomerular filtration rate (GFR) between 5 and 105 ml/min and in 4 patients on hemodialysis. In patients with normal renal function the mean half life of elimination was calculated to be 6.8 h. This value increased to a mean of 50.1 h in patients with a GFR below 10 ml/min. In patients on hemodialysis the half life of elimination was about 4 h. The elimination rate constants as well as the body and renal clearances of atenolol have a significant correlation with the GFR. Although accumulation of atenolol was observed, especially after multiple oral doses and in patients with a GFR below 30 ml/min, no toxic side effects occured.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Barrett, A. M., Carter, J., Fitzgerald, J. D., Hull, R., LeCount, D.: A new type of cardioselective adrenoceptive blocking drug. Brit. J. Clin. Pharmacol. 48, 340–346 (1973)

    Google Scholar 

  • Conway, F. J., Fitzgerald, J. D., McAinsh, J., Rowlands, D. J., Simpson, W. T.: Human pharmacokinetics and pharmacodynamic studies on atenolol (ICI 66, 082) a new cardioselective beta-adrenoceptor-blocking drug. Brit. J. Clin. Pharmacol. 3, 267–272 (1976)

    CAS  Google Scholar 

  • Milutinovic, J., Cutter, R. E., Hoover, P., Hujesin, B., Scribner, B. H.: Measurement of residual glomerular filtration rate in the patients receiving repetitive hemodialysis. Kidney Int. 8, 185–188 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Sassard, J., Pozet, N., McAinsh, J., Legheard, J., Zech, P.: Pharmacokinetics of atenolol in patients with renal impairment. Europ. J. Clin. Pharmacol. 12, 175–180 (1977)

    Article  CAS  Google Scholar 

  • Seiler, K. U., Meyer, G. J., Niedermayer, W., Wassermann, O.: Die Bedeutung der Pharmakokinetik für die antihypertensive Therapie niereninsuffizienter Patienten mit Propa-nolol oder Atenolol. 89. Tagung der Nordwestdeutschen Gesellschaft für Innere Medizin, 1977, Malente

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Springer-Verlag

About this paper

Cite this paper

Kirch, W., Schäfer, M., Braun, M. (1980). Single Intravenous Dose Kinetics and Accumulation of Atenolol in Patients with Impaired Renal Function and on Hemodialysis. In: Chambers, P.L., Klinger, W. (eds) Further Studies in the Assessment of Toxic Actions. Archives of Toxicology, vol 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67729-8_79

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-67729-8_79

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-10191-8

  • Online ISBN: 978-3-642-67729-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics